Transaction DateRecipientSharesTypePriceValue
28th December 2020Stephen Connelly25,000Open or private sale$4.52$113,045.00
23rd December 2020Jason A Keyes8,000Open or private sale$4.74$37,913.60
28th September 2020Stephen Connelly25,000Open or private sale$5.62$140,395.00
13th July 2020Stephen Connelly250,000Open or private sale$8.13$2,033,475.00
10th June 2020Jason A Keyes5,014Other acquisition or disposition$2.41$12,083.74
10th June 2020Christine Zedelmayer9,570Other acquisition or disposition$2.41$23,063.70
18th February 2020Jason A Keyes5,000Open or private sale$5.03$25,137.50
21st January 2020Jason A Keyes5,000Open or private sale$4.41$22,043.00
3rd September 2019Jason A Keyes5,000Open or private sale$3.60$17,980.50
1st August 2019Jason A Keyes5,000Open or private sale$3.99$19,941.00
Equillium logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 9/10.

Equillium, Inc. is a biotechnology company, which engages in the development of products for severe immuno-inflammatory disorders with high unmet medical need. The company was founded by Daniel Mark Bradbury, Bruce D. Steel, and Stephen Connelly on March 16, 2017 and is headquartered in La Jolla, CA.

Ticker: EQ
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 1746466
Employees: 16
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags